1516 - Testing for epidermal growth factor receptor (EGFR) status in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) to determine eligibility for osimertinib

Page last updated: 07 October 2020

Application Detail

Description of Medical Service

Testing for EGFR gene mutation in patients with locally advanced or metastatic NSCLC.

Description of Medical Condition

Lung cancer is the second leading cause of premature death for all Australians and is the fifth most commonly diagnosed cancer in Australia. NSCLC cancer accounts for over 80% of all lung cancer cases, and is usually diagnosed at an advanced stage when surgical resection may no longer be amenable.

Reason for Application

Amendment to MBS item

Medical Service Type


Previous Application Number

Not Applicable

Associated Documentation

Application Form

Application Form (Word 188 KB)
Application Form (PDF 830 KB)

Consultation Survey

Consultation Survey (Word 508 KB)
Consultation Survey (PDF 305 KB)

PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document (Word 69 KB)
Public Summary Document (PDF 710 KB)

Meetings for this Application






28-29 July 2020